JOHNSON & JOHNSON is 2.0x more valuable than Novartis AG by market capitalization ($573.98 B vs $283.13 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | JNJ | NVS |
|---|---|---|
| Market cap | $573.98 B | $283.13 B |
| US-listed rank | #20 | #47 |
| Revenue (latest FY) | $94.19B | - |
| Net income (latest FY) | $26.80B | - |
| Net margin | 28.5% | - |
| P/E (trailing FY) | 21.4 | - |
| SEC filings | 984 | 947 |
JOHNSON & JOHNSON is 2.0x more valuable than Novartis AG by market capitalization ($573.98 B vs $283.13 B).
Full pages: JOHNSON & JOHNSON and Novartis AG, or browse the full rankings.